Based upon preclinical studies, E-selectin antagonist, GMI-1271, has the potential to disrupt known pathways of tumor resistance, thereby increasing the efficacy of chemotherapy. It may also address both metastasis (cancer’s spread) and thromboembolic complications (those occurring when a blood vessel is blocked by a blood clot dislodged from its site of origin). In addition, in preclinical models, GMI-1271 reduces neutropenia and mucositis caused by chemotherapy. We have selected acute myeloid leukemia (AML) and multiple myeloma (MM) as the initial target disease indications for the compound and announced in May 2015 the initiation of a Phase 1/2 clinical trial of GMI-1271 as a potential treatment for AML in combination with chemotherapy. In June 2016 GlycoMimetics announced the initiation of the Phase 2 portion of this trial. In September 2016, the Company initiated a Phase 1 clinical trial in Ireland of GMI-1271, in combination with bortezomib-based chemotherapy, in multiple myeloma. We have conducted preclinical studies to explore the compound’s use in blood cancers and other cancers that are also associated with elevated risk of metastasis and thrombosis, and also completed a trial of the drug candidate in healthy volunteers. GMI-1271 has not been approved for use by any worldwide health authority.
Visit our Scientific Publications page to review data for GMI-1271 that have been presented at medical meetings.
» Read more about our Pipeline & Other Programs.